Pulse Biosciences, Inc (PLSE) News
Filter PLSE News Items
PLSE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PLSE News Highlights
- For PLSE, its 30 day story count is now at 4.
- Over the past 22 days, the trend for PLSE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- EP are the most mentioned tickers in articles about PLSE.
Latest PLSE News From Around the Web
Below are the latest news stories about PULSE BIOSCIENCES INC that investors may wish to consider to help them evaluate PLSE as an investment opportunity.
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP SummitHAYWARD, Calif., September 29, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE, "the Company"), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29th to 30th, 2023. |
Pulse Biosciences’ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual MeetingHAYWARD, Calif., September 27, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE, "the Company"), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in two poster presentations at the upcoming American Thyroid Association 2023 Annual Meeting in Washington D.C. from September 27th to October 1st, 2023. |
Pulse Biosciences Insiders Added US$65m Of Stock To Their HoldingsOver the last year, a good number of insiders have significantly increased their holdings in Pulse Biosciences, Inc... |
Pulse Biosciences to Present at Gilmartin Group Emerging Growth ShowcaseHAYWARD, Calif., September 07, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE, "the Company"), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to participate at the upcoming Gilmartin Group Emerging Growth Showcase, taking place virtually. Members of management are scheduled to present on Thursday, September 21, 2023 at 10:30am PT. |
We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Pulse Biosciences... |
Pulse Biosciences Clarifies Details of Recent S-3 FilingHAYWARD, Calif., August 24, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE, "the Company"), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today provided additional clarification regarding the details of the SEC form S-3 ("the filing") filed August 11, 2023. |
Q2 2023 Pulse Biosciences Inc Earnings CallQ2 2023 Pulse Biosciences Inc Earnings Call |
Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial ResultsHAYWARD, Calif., August 10, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the second quarter ended June 30, 2023. |
Pulse Biosciences, Inc. (NASDAQ:PLSE) insiders have had a fantastic week as stock increased 31%, and they haven't stopped buyingKey Insights Pulse Biosciences' significant insider ownership suggests inherent interests in company's expansion 76% of... |
Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023HAYWARD, Calif., July 27, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced today it will report financial results for the second quarter of 2023 after market close on Thursday, August 10, 2023. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. |